Milvia Casato

Milvia Casato

Auto-generated profile, based on publicly available information

Milvia Casato

Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2016 in Blood
Verified
Journal Article
Closed access
PDF file
LALuca Arcaini
Luca Arcaini
CBCaroline Besson
Caroline Besson
MFMarco Frigeni
Marco Frigeni
HFHélène Fontaine
Hélène Fontaine
MGMaria Goldaniga
Maria Goldaniga
OHOlivier Hermine
Olivier Hermine
Regression of hepatitis C virus (HCV)–associated lymphoma with interferon (IFN)-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCV-related lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty. We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs. The histological distribution was 37 marginal zone lymphomas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified. Thirty-nine patients received a sofosbuvir-based regimen and 7 patients received other DAAs. The median duration of DAA therapy was 12 weeks (range, 6-24 weeks). A sustained virological response at week 12 after finishing DAAs was obtained in 45 patients (98%); the overall LDR rate was 67%, including 12 patients (26%) who achieved a complete response. The LDR rate was 73% among patients with MZL, whereas no response was observed in CLL/SLL patients. Seven patients cleared cryoglobulins out of 15 who were initially positive. After a median follow-up of 8 months, 1-year progression-free and overall survival rates were 75% (95% confidence interval [CI], 51-88] and 98% [95% CI, 86-100], respectively. DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Direct-acting antiviral agents are able to induce lymphoma response in patients with HCV-associated indolent non-Hodgkin lymphoma. The highest rate of lymphoma response (73%) was observed in patients with marginal zone lymphoma.

1 October 1987 in The American Journal of Medicine
Verified
Journal Article
Closed access
LBLorenzo Bonomo
Lorenzo Bonomo
MCMilvia Casato
Milvia Casato
AAAntonella Afeltra
Antonella Afeltra
DCDomenico Caccavo
Domenico Caccavo

1 April 1991 in The Lancet
Verified
Journal Article
Closed access
MCM. Casato
M. Casato
LPL.P. Pucillo
L.P. Pucillo
Bruno LaganàBruno Laganà
Bruno Laganà
Gloria TalianiGloria Taliani
Gloria Taliani
FGF. Goffredo
F. Goffredo
LBL. Bonomo
L. Bonomo

1 September 2011 in Autoimmunity Reviews
Verified
Journal Article
Closed access
MVMarcella Visentini
Marcella Visentini
SLSerena Ludovisi
Serena Ludovisi
APAntonio Petrarca
Antonio Petrarca
FPFederica Pulvirenti
Federica Pulvirenti
MZMarco Zaramella
Marco Zaramella
MCMilvia Casato
Milvia Casato

17 July 2014 in Genes & Immunity
Verified
Journal Article
Open access
PDF file
AZA L Zignego
A L Zignego
GWG L Wojcik
G L Wojcik
PCPatrice CACOUB
Patrice CACOUB
MVMarcella Visentini
Marcella Visentini
MCM Casato
M Casato
PDP Duggal
P Duggal
The host genetic basis of mixed cryoglobulin vasculitis is not well understood and has not been studied in large cohorts. A genome-wide association study was conducted among 356 hepatitis C virus (HCV) RNA-positive individuals with cryoglobulin-related vasculitis and 447 ethnically matched, HCV RNA-positive controls. All cases had both serum cryoglobulins and a vasculitis syndrome. A total of 899 641 markers from the Illumina HumanOmni1-Quad chip were analyzed using logistic regression adjusted for sex, as well as genetically determined ancestry. Replication of select single-nucleotide polymorphisms (SNPs) was conducted using 91 cases and 180 controls, adjusting for sex and country of origin. The most significant associations were identified on chromosome 6 near the NOTCH4 and MHC class II genes. A genome-wide significant association was detected on chromosome 6 at SNP rs9461776 (odds ratio=2.16, P=1.16E−07) between HLA-DRB1 and DQA1: this association was further replicated in additional independent samples (meta-analysis P=7.1 × 10−9). A genome-wide significant association with cryoglobulin-related vasculitis was identified with SNPs near NOTCH4 and MHC Class II genes. The two regions are correlated and it is difficult to disentangle which gene is responsible for the association with mixed cryoglobulinemia vasculitis in this extended major histocompatibility complex region.

15 March 2002 in Blood
Verified
Journal Article
Closed access
PDF file
MCMilvia Casato
Milvia Casato
CMCristina Mecucci
Cristina Mecucci
VAVincent Agnello
Vincent Agnello
MFMassimo Fiorilli
Massimo Fiorilli
GKGlenn B. Knight
Glenn B. Knight
JKJonathan Kay
Jonathan Kay
A patient with type II cryoglobulinemic vasculitis and hepatitis C virus (HCV) infection presented with a leukemiclike proliferation of B cells bearing marginal zone B-cell phenotypic markers. A partial trisomy 3 (bands 3q11–29) and overexpression of Bcl-2 without t(14;18) translocation was detected in the monoclonal B cells that were classic rheumatoid factor–producing B cells bearing the WA cross-idiotype. Treatment with interferon-α produced a complete clinical remission and synchronous marked decreases in viremia and monoclonal B-cell prevalence. This is the first report of partial trisomy 3 and Bcl-2 overexpression in type II cryoglobulinemic vasculitis associated with HCV infection. Further studies of HCV-infected patients with and without type II cryoglobulinemia are required to determine the prevalence and possible physiologic and/or pathophysiologic significance of these findings.